About: Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.99 (-0.10%)
ANVS NYSE Annovis Bio Inc
Annovis Bio Inc share price
Atividade de preço de ANVS
Último preço
$ 0,990
Variação (24h)
-0,00 USD (0,10%)
Volume
315.62K
Volume (média 4 sem.)
-
Abertura
$ 1,00
Variação do dia
$ 0,96 - $ 1,01
Fechamento anterior
$ 0,99
Último negócio
23 Oct, 8:00 pm GMT+0
Atrasado
23 Oct, 8:00 pm GMT+0
ANVS price performance
Atrasado
23 Oct, 8:00 pm GMT+0
quote.marketSignals